AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04544293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molgramostim
Description: Molgramostim 300 µg nebulizer solution
Study NCT04544293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Molgramostim
Description: Molgramostim 300 µg nebulizer solution
Study NCT04544293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT04974151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine besylate
Description: The amlodipine used in this study is a listed product.
Study NCT04974151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine besylate And Folic Acid
Description: The amlodipine besylate and folic acid tablets have been approved for listing by the China Food and Drug Administration, approval number: Zhunzi H20180020.
Study NCT04974151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-methyltetrahydrofolate (5-MTHF)
Description: The 5-MTHF used in this study is a listed product.
Study NCT04974151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine placebo
Description: Amlodipine placebos are dummy pills of amlodipine with identical appearance.
Study NCT04974151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine folic acid placebo
Description: Amlodipine folic acid placebos are dummy pills of amlodipine folic acid with identical appearance.
Study NCT04974151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-MTHF Placebos
Description: 5-MTHF placebos are the dummy pills of 5-MTHF with identical appearance.
Study NCT04974151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-MTHF Placebos
Description: 5-MTHF placebos are the dummy pills of 5-MTHF with identical appearance.
Study NCT05922761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil
Description: Kinase inhibitor, tablet taken orally
Study NCT05922761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone
Description: Via inhalation by metered-dose inhaler.
Study NCT05922761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Semi-synthetic macrolide antibiotic, taken orally
Study NCT05922761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Corticosteroid, taken orally
Study NCT05922761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Leukotriene Receptor Antagonist, taken orally
Study NCT06370728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally
Study NCT06370728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Administered orally
Study NCT05918783 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Padeliporfin Vascular Targeted Photodynamic (VTP) therapy
Description: Bronchoscopy will be performed with robotic assisted approach using standard practices using general anaesthesia and placement of the optic fiber intratumorally followed by IV administration of Padeliporfin for 10 min and laser light illumination.
Study NCT06281353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin Oral Capsule
Description: Curcumin oral capsule in nano-sized particle.
Study NCT06281353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trichloroacetic acid
Description: TCA 90%
Study NCT06281353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trichloroacetic acid
Description: TCA 90%
Study NCT06281353 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Description: HIV and CD4+ 4th generation.
Study NCT06281353 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood sample collection
Description: HIV and CD4+ 4th generation.
Study NCT06281353 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cotton swab
Description: Cotton swab for collecting sample from AGW lesions.
Study NCT06281353 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cotton swab
Description: Cotton swab for collecting sample from AGW lesions.
Study NCT06464367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: synthetic psilocybin 10 mg (oral)
Study NCT06094257 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sensory testing
Description: Quantitative sensory testing (QST) will be performed. QST was developed to standardize the noninvasive assessment of the somatosensory nervous system and quantify functioning of all aspects of sensation (light touch, pressure, warm, cold, pain, vibration): 1. Thermal detection (Medoc TSA system): Cold detection threshold B) Warm detection threshold C) Heat pain threshold 2. Mechanical detection threshold (MRC Opti Hair von Frey Filaments) 3. Two-point discrimination (MRC Opti Hair von Frey Filaments) 4. Mechanical pain threshold (MRC Pinprick Stimulator) 5. Pressure pain threshold (Medoc Pressure algometer) 6. Tinel sign on physical exam 7. Vibration (tuning fork)
Study NCT06268340 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ECochG monitored CI surgery incl. corrective action guide
Description: Interventional surgery with surgeon having access to intra-operative ECochG monitoring feedback to deploy ECochG based corrective action guide
Study NCT06268340 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine CI surgery without ECochG monitoring
Description: Routine CI surgery with access to ECochG monitoring by surgeon
Study NCT05402969 — intervention group
Intervention type: PROCEDURE
Intervention: Transimedance Matrix measurements
Description: TIM measurements are based on cochlear implant back-telemetry function. Each electrode contact is stimulated in monopolar mode. Transimpedance is represented by the ratio between the voltage measured at each recording electrode and the current injected at the stimulation contact. The result of the measurements is a matrix of 21x21 transimpedances. Stimulation current cannot be perceived by a patient thus making TIM measurements a non-invasive and painless procedure. The test duration is only 2-3 minutes
Study NCT05402969 — intervention group
Intervention type: PROCEDURE
Intervention: Depth sounding and spectroscopy
Description: Depth sounding and spectroscopy are based on the matrixes obtained after TIM imaging. Deep sounding measures the capacitances throughout the electrode array whereas spectroscopy determines the phase of every transimpedance value. These tests take 10 to 15 minutes together. The stimulation intensity used by depth sounding technique can be perceived by a patient. If it is considered as unpleasant, the test will be stopped.
Study NCT05402969 — intervention group
Intervention type: PROCEDURE
Intervention: Cone Beam Computer Tomography
Description: CBCT is a routine postoperative assessment after CI, non-invasive and painless for patients.
Study NCT05241535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117
Description: oral
Study NCT04439968 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical algorithm
Description: In order to maintain cerebral saturations within targeted range, subjects in the targeted Csat arm will undergo clinical interventions based on clinical algorithm. Interventions may include administration of inotropes, fluid resuscitation, transfusion of blood products, and/or adjustment to respiratory support.
Study NCT05241535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: oral
Study NCT06464367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: synthetic THC 2.5 mg (oral)
Study NCT05241535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral
Study NCT05159310 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cast vs Splint
Description: Patients presenting with DRF will be screened by the attending consultant. The temporary backslab will be removed, X-rays will be obtained, and the attending consultant will discuss the treatment options. Patients who are planned for non-operative treatment and meet the inclusion criteria will be eligible for the study. The purpose and details of the study will be explained and informed consent will then be taken by the research coordinator (RC). The participants will then be randomized (using a block-randomization method) to either treatment by splint or cast.
Study NCT04560764 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participants in both groups will attend 10 sessions of approximately 30 minutes each three times a week. Each session contemplates the execution of a single repetition of two minutes of each of the four exercises.~There are four exercises:~1. Reaching: the participant is requested to reach a target in front of him with the paretic hand; the target will appear in a different place every time;~2. Reaching and grasping: the participant is requested to grab a wooden cube with the paretic hand and place it into a bowl positioned in front of him; the cube will appear in a different place every time;~3. Goalkeeper: the participant is requested to block a ball coming towards him with the paretic hand; the ball will appear in a different place every time;~4. Occupational task: the participant is requested to grab four cans, one at time, with the paretic hand and place them on four targets placed on a hemispherical arch.~Each exercise provides six levels of increasing difficulty.
Study NCT04560764 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Virtual Reality
Description: Participants in both groups will attend 10 sessions of approximately 30 minutes each three times a week. Each session contemplates the execution of a single repetition of two minutes of each of the four exercises.~There are four exercises:~1. Reaching: the participant is requested to reach a target in front of him with the paretic hand; the target will appear in a different place every time;~2. Reaching and grasping: the participant is requested to grab a wooden cube with the paretic hand and place it into a bowl positioned in front of him; the cube will appear in a different place every time;~3. Goalkeeper: the participant is requested to block a ball coming towards him with the paretic hand; the ball will appear in a different place every time;~4. Occupational task: the participant is requested to grab four cans, one at time, with the paretic hand and place them on four targets placed on a hemispherical arch.~Each exercise provides six levels of increasing difficulty.
Study NCT04560764 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Action Observation Therapy
Description: Before the execution of the exercises described in the intervention Virtual Reality, the participants in the experimental group will see a video demonstrating the same exercise (according to the level of difficulty selected) he will be later asked to perform for two minutes.
Study NCT04259424 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise + Duck Duck Punch
Description: Subjects will perform 15 minutes of aerobic exercise on a recumbent stationary cycle. On each session the target intensity of aerobic exercise will be 70% heart rate reserve.~Following a 10-minute rest break subjects will perform 200 repetitions on an upper extremity rehabilitation game called Duck Duck Punch (DDP). Duck Duck Punch is an interactive game with an old school carnival theme. DDP is unique as it uses Microsoft Kinect skeletal tracking technology to assess movement performance. The participant sits in front of the Microsoft Kinect and controls a virtual arm with his/her physical arm; reaching forward to punch virtual ducks. A therapist will oversee the subject's safety and progress during DDP. DDP will be dosed based on the number of repetitions performed. A repetition is recorded when the player moves his/her arm so that the avatar leaves a start position. The goal dose for subjects will be 200 repetitions per DDP session.
Study NCT04614233 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RiduZone (90% OEA)
Description: Participants will be randomly assigned to take 2 capsules of RiduZone (each capsule contains 90% OEA ) daily for 16 months
Study NCT05628038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: PD-1 antibody (Toripalimab): 240mg q3w or 160mg q2w
Study NCT05628038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: 1000mg/m2 d1-14 q3w
Study NCT05628038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU
Description: 400 mg/m2 (bolus) and 2400 mg/m2 (continuous infusion for 48hr)
Study NCT05628038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folinic acid
Description: 400 mg/m2 q2w
Study NCT05628038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m² q3w or 85 mg/m² q2w
Study NCT05628038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m² q2w and 200 mg/m² q3w
Study NCT04614233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomly assigned to take 2 capsules of placebo daily for 16 months. Placebo capsules will consist of 180mg of hypromellose.
Study NCT06399289 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP)
Description: Lyophilized powder for solution for intravenous injection
Study NCT06458920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social regulation
Description: Participants will regulate emotion with the help of a friend
Study NCT06458920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive regulation
Description: Participants will regulate emotion on their own
Study NCT05807659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fractionated busulfan-based conditioning regimen
Description: Drug: Chidamide 30 mg oral twice weekly for 2 weeks Drug: Fludarabine 35 mg/m2 intravenously daily for 5 days in the 2nd week Drug: Cytarabine~1 g/m2 intravenously for 5 days in the 2nd week Drug: Busulfan 3.2 mg/kg intravenously daily for 2 days in the 1st week, 1.6 mg/kg intravenously daily for 4 days in the 2nd week Procedure/Surgery: allogeneic hematopoietic stem cell transplantation
Study NCT06460558 — intervention group
Intervention type: OTHER
Intervention: Type 1 diabetes with insulin infusion system
Description: No intervention
Study NCT05628038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Description: 2 mg/m² q2w and 3 mg/m² q3w
Study NCT05628038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 400 mg/m² q2w
Study NCT05628038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg q2w or 7.5mg/kg q3w
Study NCT05628038 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 25-40Gy/5Fx irradiation or 15-30Gy/5Fx reirradiation (pelvic radiation history) for pelvic recurrence tumor.~35-60Gy/5-8Fx irradiation for distance metastasis tumor.
Study NCT06239194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDX2001
Description: MDX2001 intravenous infusion
Study NCT06138262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health promotion of education pre-conception nutritional preparation
Description: Providing education on pregnancy nutritional preparation during the preconception period 3 months before the wedding
Study NCT05770271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The novel electrolyzed water spray
Description: Study staff will use the novel electrolyzed water spray device and spray for approximately 5 minutes on the participant's diseased area until half a bottle (200ml) of water is used. The patients use electrolyzed water to treat the diseased area, two times a day, for 10 days. The trial consists of 10 study visits (day 1-day 10). The relief of mild senile groin eczema, neurodermatitis and psoriasis evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
Study NCT05778435 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wireless fetal monitoring system
Description: The wireless fetal monitoring system shortens the period of labor by enabling the woman to be more mobile during the intrapartum period.
Study NCT05936606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel monotherapy
Description: Patients will receive clopidogrel monotherapy (75 mg qd) for 24 months after randomization, irrespective of PRU value or bleeding risk.
Study NCT05936606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tailored anti-platelet therapy
Description: In the tailored therapy arm, non-HPR (PRU\<208) patients will continue clopidogrel monotherapy until the end of the study at 24 months from randomization, while HPR (PRU≥208) patients will receive dual anti-platelet therapy according to the clinical diagnosis at the time of drug-eluting stent placement: High-risk patients with prior myocardial infarction will receive ticagrelor 60 mg twice daily wiht aspirin 100 mg daily, while the remainder will receive clopidogrel 75 mg daily with aspirin 100 mg daily. For HBR patietns, early cessation of dual antiplatelet therapy or aspirin monotherapy could be considered at the investigator's discretion.
Study NCT05397912 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Uterine Elastography
Description: Shear wave elastography data will be obtained at the transvaginal ultrasound visit the day prior to frozen embryo transfer
Study NCT03865615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: intranasal oxytocin 40IU/mL
Study NCT03865615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT06228352 — intervention group
Intervention type: OTHER
Intervention: Feces collection
Description: A single stool sample will be taken (a specific kit will be given to the patient for this) during a consultation for follow-up or hospitalization.~Stool samples will be used to study the composition of the intestinal microbiota and to measure faecal biomarkers.
Study NCT05449301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythmic Auditory Stimulation
Description: The participants will receive RAS on regular treadmill for balance and gait improvement. one session per day, 3 session per week for consecutively 12 weeks.
Study NCT05449301 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill Training
Description: participants will be trained conventionally (bipedal) on regular treadmill. one session per day, 3 session per week for consecutively 12 weeks.
Study NCT05449301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill Training
Description: participants will be trained conventionally (bipedal) on regular treadmill. one session per day, 3 session per week for consecutively 12 weeks.
Study NCT05449301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unilateral Step Training
Description: Patients will be trained on regular treadmill for both paretic and non paretic lower extremity. Single session per day, 3 session per week for consecutively 12 weeks.
Study NCT05967832 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 7T MRI
Description: Patients and healthy volunteers will have a 7T MRI
Study NCT05967832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 7T MRI
Description: Patients and healthy volunteers will have a 7T MRI
Study NCT04588870 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre operative computer based cochlear implant surgical simulation
Description: Prior to surgery, the surgeon will perform virtual cochlear implant surgery on patient specific imaging data within a computer simulation program. The surgeon will be able to iterate the procedure on the simulator until achieving the best electrode array location is achieved with respect to scalar location and modiolar distance. A written and graphical surgical plan will then be developed that the surgeon can use in the actual surgery.
Study NCT05050123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iPhone Google Cardboard virtual reality meditation/relaxation app
Description: Virtual reality meditation/relaxation app that has 6 scenes of 360° visual imagery with soothing music. The patient can spend about 15 minutes exploring the app.
Study NCT05050123 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard relaxation training
Description: 15 minute sessions of guided imagery using Mayo Clinic Patient Education CD-ROM Relaxation for Your Mind and Body
Study NCT06402448 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: muscle pain , joint pain and nerve pain.
Description: to discover the percentage of each tissue that causing pain even it is muscle, joint or nerve in patients with spinal disorders.
Study NCT05667116 — intervention group
Intervention type: DRUG
Intervention: EVUSHELD
Description: EVUSHELD (AZD 7442, Tixagévimab/Cilgavimab)
Study NCT05419180 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Stiripentol
Description: Since the treatment usually received by patients should not be modified, the sponsor will not intervene in any way in the therapeutic management of patients.
Study NCT06137131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Straw phonation in air
Description: Phonation (/u/ vowel) through a stirring straw (3 mm diameter, 20cm length) in air
Study NCT06137131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: straw phonation in water
Description: Phonation (/u/ vowel) through a stirring straw (3 mm diameter, 20cm length) in 2 cm or 5 cm water
Study NCT06137131 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: /u/ phonation
Description: /u/ phonation without a straw, control condition